Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence
If a patient develops tardive dyskinesia, should the antipsychotic dose be reduced? Should the patient stop taking it? What does the evidence say?
Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics. While prevention is the best strategy, it is not always possible. This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).
From the Series: JCP Fundamentals: Getting Back to the Basics—Diagnosing, Treating, and Educating Patients With Tardive Dyskinesia
To cite: McEvoy J. Selecting treatment for patients with tardive dyskinesia using safety and efficacy evidence. J Clin Psychiatry. 2020;81(6):NU19047BR3C.
To share: https://doi.org/10.4088/JCP.NU19047BR3C
© Copyright 2020 Physicians Postgraduate Press, Inc.
Psychiatrists, neurologists, nurse practitioners, and physician assistants
Select FDA-approved medication to treat TD symptoms
Supported by an educational grant from Neurocrine Biosciences, Inc.
After completing this educational activity, you should be able to:
- Select FDA-approved medication to treat TD symptoms
Release, Review, and Expiration Dates
This brief report activity was published in September 2020 and is eligible for AMA PRA Category 1 Credit™ through September 30, 2022. The latest review of this material was August 2020.
Statement of Need and Purpose
Clinicians may not recognize early TD symptoms, as mild cases may be more easily missed. A substantial proportion of patients with TD do not have a timely diagnosis, meaning that treatment is delayed and the chance for a poor outcome is increased. Because some clinicians underestimate the risk of TD, especially with newer antipsychotics, they do not advise patients and caregivers of the risk of TD or educate them about early signs to watch for and report. Therefore, clinicians need education on the rates of TD with SGAs and FGAs; risk factors for the development of TD; how to use assessment tools that will help them diagnose and monitor TD; and discussing TD risk and signs with patients and caregivers. In addition, physicians need awareness of evidence-based, expert guidance on using approved medications in the treatment of TD, because effective medications for TD are available, and evidence-based treatment recommendations have been published. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on TD.
Disclosure of Off-Label Usage
Dr McEvoy has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this activity.
The faculty member agreed to provide a balanced and evidence-based presentation and discussed the topic and CME objective during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
This activity is derived from the teleconference series “ JCP Fundamentals: Getting Back to the Basics—Diagnosing, Treating, and Educating Patients With Tardive Dyskinesia,” which was held in March–September 2020 and supported by an educational grant from Neurocrine Biosciences, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.
Joseph P. McEvoy, MD
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University
The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure is as follows:
Dr McEvoy has received grant/research support from Biogen, Alkermes, Boehringer Ingelheim, Takeda, Auspex (Teva), and Lundbeck and is a member of the speaker/advisory boards for Intracellular and Sunovion.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
MOC Approval Statement
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
MOC Part II CME Activity
Psychiatry and Neurology
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation